Skip to main content
Premium Trial:

Request an Annual Quote

Elucidata to Support Auron Therapeutics in Cancer Data Analysis

NEW YORK (GenomeWeb) – Elucidata, a developer of analytics software to support drug discovery, has signed a four-year contract with startup biotech firm Auron Therapeutics to provide data analytics for differentiation-based cancer therapies. Financial terms were not disclosed.

Wellesley, Massachusetts-based Auron Therapeutics, which launched this year, will leverage Elucidata's cloud-based data analytics platform called Polly to to analyze transcriptomic, metabolomic, and epigenetic data from biological samples, the companies said. Auron is seeking to identify and validate targets for differentiation-based therapy for acute myeloid leukemia and eight other types of cancer.

"With our platform, we are seeking to develop an atlas of differentiation paths of healthy and diseased cells that will help us identify and characterize disease mechanisms," Elucidata Cofounder and CEO Abhishek Jha said in a statement. "This collaboration with Auron is an incredible opportunity to realize the promise of big-data analytics to discover new targets that will deliver more precise medicine to patients."

Cambridge, Massachusetts-based Elucidata raised $1.7 million in a seed funding round that closed in June.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.